$25 Million

Sunesis Pharmaceuticals

Follow-on Offering

Sole Bookrunner, December 2015

Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s lead product candidate, SNS-062, is a non-covalent BTK inhibitor intended for B-cell malignancies. The asset is currently in a Phase Ib/II study with initial data expected in the first half of 2018 in CLL, MCL and WM. SNS-062 demonstrated a favorable PK / PD profile with sustained target inhibition in a Phase Ia study in healthy volunteers. As a non-covalent BTK inhibitor, data suggest that it may overcome the acquired resistance to covalent clinical-stage inhibitors that results from a point mutation in the BTK active site.